The abstract is read at the publisher; the summary is JClub's.
Lipid-enriched senescent T cells are abundant across breast, colorectal, and lung cancers and actively reprogram tumor cells to drive growth, stemness, metastasis, and chemotherapy resistance.
- Why it matters: Immune senescence is linked to tumor progression, but direct evidence that senescent T cells can reprogram tumor-cell behavior and therapy response was missing.
- What they did: Single-cell transcriptomics identified abundant Tsen cells in multiple cancer types; lipid-rich SASPs from these cells were tested for effects on tumor cells in vitro and in vivo, with STAT1/STAT3 activation assessed.
- The result: Depleting Tsen cells or disrupting tumor lipid metabolic reprogramming suppressed Tsen-mediated tumor progression and metastasis in vivo, supporting lipid-rich SASP-dependent immune–tumor communication as a therapeutic target.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.